Saturday, 17 October 2026European Markets

EQVA Stock Was Up By 12% Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with EQVA (EQVA.OL) rising 12% to kr4.48 on Friday while Oslo Børs Benchmark Index_GI rose 0.52% to kr1,416.42.

EQVA's last close was kr4.48, 12% higher than its 52-week high of kr4.00.

About EQVA

Eqva ASA, provides technical solutions and services to maritime and land based industries in Norway and internationally. It operates in three segments: Products, Solutions & Renewables; Real Estate; and Other. The company provides technical installations to the land-based and maritime industry; and develops and operates small-scale hydropower plants. It also engages in real estate business. The company was formerly known as Havyard Group ASA and changed its name to Eqva ASA in November 2022. Eqva ASA was incorporated in 1999 and is headquartered in Kvinnherad, Norway.

Earnings Per Share

As for profitability, EQVA has a trailing twelve months EPS of kr-0.33.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.45%.

More news about EQVA (EQVA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com